Compositions and methods for treating and preventing adhesions and ilues

Abstract

Disclosed herein are pharmaceutical compositions useful for the treatment and prevention of adhesions and ilcus.

1 . A method for treating or preventing adhesions or ileus in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an aqueous pharmaceutical composition comprising tranexamic acid, polyethylene glycol, glucose, and at least one electrolyte. 
     
     
         2 . The method of  claim 1 , wherein the aqueous pharmaceutical composition is administered to the patient prior to a surgical procedure. 
     
     
         3 . A method for treating or preventing adhesions or ileus in a patient in need thereof comprising orally administering to the patient a therapeutically effective amount of an aqueous pharmaceutical composition prior to a surgical procedure to treat or prevent adhesions or ileus; wherein the aqueous pharmaceutical composition comprises tranexamic acid, polyethylene glycol, glucose, and at least one electrolyte. 
     
     
         4 . The method of  claim 1 , wherein the adhesions are surgical adhesions. 
     
     
         5 . The method of  claim 1 , wherein the adhesions are abdominal adhesions. 
     
     
         6 . The method of  claim 1 , wherein the adhesions are intestinal adhesions. 
     
     
         7 . The method of  claim 1 , wherein the adhesions are peritoneal adhesions. 
     
     
         8 . The method of  claim 1 , wherein the adhesions are intercostal adhesions. 
     
     
         9 . The method of  claim 1 , wherein the adhesions are abdominal adhesions, intestinal adhesions, peritoneal adhesions, or a combination of two or more thereof. 
     
     
         10 . The method of  claim 1 , wherein treating or preventing adhesions comprises:
 (i) reducing the incidence of adhesions; (ii) reducing the number of adhesions; (iii) reducing the severity of adhesions; (iv) reducing the thickness of adhesions; (v) reducing the size of the adhesions; (vi) preventing the formation of adhesions; or (vii) a combination of two or more of (i), (ii), (iii), (iv), (v), and (vi).   
     
     
         11 . The method of  claim 1 , wherein treating or preventing adhesions comprises reducing the number of adhesions, reducing the severity of adhesions, or a combination thereof. 
     
     
         12 . The method of  claim 1 , wherein treating or preventing adhesions or ileus comprises reducing a complication caused by adhesions or ileus, or reducing a co-morbidity caused by adhesions or ileus. 
     
     
         13 . The method of  claim 12 , wherein the complication caused by adhesions or ileus is delayed bowel function recovery, intestinal obstruction, infertility, pain, or a combination of two or more thereof. 
     
     
         14 . The method of  claim 2 , comprising orally administering the composition to the patient. 
     
     
         15 . The method of  claim 2 , comprising orally administering a first dose of about 300 ml to about 400 ml of the aqueous pharmaceutical composition about 6 hours to about 8 hours prior to the surgical procedure, and orally administering a second dose of about 300 ml to about 400 ml about 2 hours to about 5 minutes prior to the surgical procedure. 
     
     
         16 . The method of  claim 1 , comprising administering the composition to the patient by lavage. 
     
     
         17 . The method of  claim 16 , comprising administering the composition to the peritoneal cavity of the patient by lavage. 
     
     
         18 . The method of  claim 16 , comprising administering the composition to an intercostal space in the patient. 
     
     
         19 . The method of  claim 16 , comprising administering the composition to the stomach, to the intestines, or to the stomach and intestines. 
     
     
         20 . The method of  claim 16 , comprising administering the composition to the patient by lavage during a surgical procedure. 
     
     
         21 .- 130 . (canceled)